These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 16055578)

  • 1. Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating.
    Haas DM; Flowers CA; Congdon CL
    Obstet Gynecol; 2005 Aug; 106(2):295-300. PubMed ID: 16055578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rubella susceptibility predicts measles susceptibility: implications for postpartum immunization.
    Libman MD; Behr MA; Martel N; Ward BJ
    Clin Infect Dis; 2000 Dec; 31(6):1501-3. PubMed ID: 11096023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
    Buxbaum S; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility to measles, rubella and parotitis in young adults].
    Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L
    Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
    Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
    Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
    Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.